Access to inhaled corticosteroids is key to improving quality of care for asthma in developing countries

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 62, Issue 3, 2007, Pages 230-236

  Ait Khaled, N ^a   Enarson, D A ^a   Bissell, K ^a   Billo, N E ^a  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

Asthma; Developing countries; Essential medicines; Inhaled corticosteroids; Quality of care

Indexed keywords

BECLOMETASONE; BUDESONIDE; CHLOROFLUOROCARBON; CORTICOSTEROID; FLUTICASONE; SALBUTAMOL; TERBUTALINE;

ASTHMA; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE QUALITY; HEALTH SERVICE; HUMAN; INCOME; LUNG DISEASE; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANTI-ASTHMATIC AGENTS; ASTHMA; COSTS AND COST ANALYSIS; DEVELOPING COUNTRIES; DRUGS, ESSENTIAL; HEALTH PRIORITIES; HUMANS; HYDROXYCORTICOSTEROIDS; INHALATION; NEEDS ASSESSMENT; POLICY MAKING;

EID: 33846994740     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2007.01326.x     Document Type: Review

References (63)

1. Masoli M, Fabian D, Holt S, Beasley R. Global burden of asthma. Developed for the Global Initiative for Asthma (GINA). Available at: http://www. ginasthma.com (Accessed 1 December 2006).
2. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9:636-642.
3. Lodha R, Puranik M, Kattal N, Kabra SK. Social and economic impact of childhood asthma. Indian Pediatr 2003;40:874-879.
4. Larbanois A, Jamart J, Delwiche JP, Vandenplas O. Socioeconomic outcome of subjects experiencing asthma symptoms at work. Eur Respir J 2002;19:1107-1113.
5. Stevens CA, Turner D, Kuehni CE, Couriel JM, Silverman M. The economic impact of preschool asthma and wheeze. Eur Respir J 2003;21:1000-1006.
6. Wang LY, Zhong Y, Wheeler L. Direct and indirect costs of asthma in school-age children. Prev Chronic Dis 2005;2:A11.
7. Herjavecz I, Nagy GB, Gyurkovits K, Magyar P, Dobos K, Nagy L et al. Cost, morbidity, and control of asthma in Hungary: The Hunair Study. J Asthma 2003;40:673-681.
8. Ait-Khaled N, Enarson D, Bousquet J. Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. Bull World Health Organ 2001;79:971-979.
9. Bousquet J, Bousquet PJ, Godard P, Daures JP. The public health implications of asthma. Bull World Health Organ 2005;83:548-554.
10. Ait-Khaled N, Enarson DA, Bencharif N, Boulahdib F, Camara LM, Dagli E et al. Implementation of asthma guidelines in health centres of several developing countries. Int J Tuberc Lung Dis 2006;10:104-109.
11. Ait-Khaled N, Enarson DA, Bencharif N, Boulahdib F, Camara LM, Dagli E et al. Treatment outcome of asthma after one year follow-up in health centres of several developing countries. Int J Tuberc Lung Dis 2006;10:911-916.
12. Sterk PJ, Buist SA, Woolcock AJ, Marks GB, Platts-Mills TAE, Von Mutius E et al. The message from the World Asthma Meeting. The Working Groups of the World Asthma Meeting, held in Barcelona, Spain, December 9-13, 1998. Eur Respir J 1999;14:1435-1453.
13. The International Study of Asthma and Allergies in Children (ISAAC) Steering Committee. Worldwide variation in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: (ISAAC). Lancet 1998;351:1225-1232.
14. Strachan D, Sibbald B, Weiland S, Ait-Khaled N, Anabwani G, Anderson HR et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997;8:161-176.
15. The International Study of Asthma and Allergies in Childhood Steering Committee. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 1998;12:315-335.
16. Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006;368:733- 743.
17. Ottmani SE, Scherpbier R, Pio A, Chaulet P, Ait-Khaled N, Blanc L et al. Practical Approach to Lung Health (PAL): a primary health care strategy for the integrated management of respiratory conditions in people five years of age and over. WHO/HTM/TB/2005.351. Geneva: World Health Organization, 2005.
18. Ottmani SE, Scherpbier R, Chaulet P, Pio A, Van Beneden C, Raviglione M. Practical Approach to Lung Health. Respiratory care in primary care services - a survey in 9 countries. WHO/HTM/TB/2004.333. Geneva: World Health Organization, 2004.
19. Sears MR. Worldwide trend in asthma mortality. Bull Int Union Tuberc Lung Dis 1991;66:79-89.
20. Sly RM. Increases in deaths from asthma. Ann Allergy 1984;53:20- 25.
21. Campbell MJ, Cogman GR, Holgate ST, Johnston SL. Age specific trends in asthma mortality in England and Wales, 1983-95: results of an observational study. BMJ 1997;314:1439-1441.
22. Anderson HR. Increase in hospital admissions for childhood asthma: trends in referral, severity, and readmissions from 1970 to 1985 in a health region of the United Kingdom. Thorax 1989;44:614-661.
23. Gilthorpe MS, Lay-Yee R, Wilson RC, Walters S, Griffiths RK, Bedi R. Variations in hospitalization rates for asthma among black and minority ethic communities. Respir Med 1998;92:642-648.
24. Partridge MR. In what way may race, ethnicity or culture influence asthma outcomes? Thorax 2000;55:175-176.
25. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992;326:862-866.
26. Stock S, Redaelli M, Luengen M, Wendland G, Civello D, Lauterbach KW. Asthma: prevalence and cost of illness. Eur Respir J 2005;25:47-53.
27. Weiss KB, Sullivan SD. The economic costs of asthma: a review and conceptual model. Pharmacoeconomics 1993;4:14-30.
28. Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Cost of asthma according to the degree of severity. Eur Respir J 1998;12:1322-1326.
29. Chouaid C, Vergnenegre A, Vanderwalle V, Liebaert F, Khelifa A, Galipon et al. The costs of asthma in France: an economic analysis by a Markov model. Rev Mal Respir 2004;21(3 Pt 1):493-499.
30. Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F et al. Asthma severity and medical resource utilization. Eur Respir J 2004;23:723-729.
31. Schwenkglenks M, Lowy A, Anderhub H, Szucs TD. Cost of asthma in a cohort of Swiss adults: associations with exacerbation status and severity. Value Health 2003;6:75-83.
32. Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ 1994;72:429-445.
33. World Health Organization. The world health report 2000: health systems: improving performance. Geneva: World Health Organization, 2000 (ISBN 92 4 156198 X).
34. Global Initiative for Asthma. Global strategy for asthma management and prevention. National Institutes of Health. National Heart Lung and Blood Institute. Updated from NHLBI/WHO Workshop Report, Issued January 1995. Revised Report 2002. Available at: http://www.ginasthma.com
35. Adelroth E, Thomson S. Advantages of high-dose inhaled budesonide. Lancet 1988;2:476 (Letter).
36. Ait-Khaled N, Enarson DA. Management of asthma in adults: a guide for low income countries. International Union Against Tuberculosis and Lung Disease. Frankfurt am Main: pmi-Verl.-Gruppe, 1996.
37. Ait-Khaled N, Enarson DA. Management of asthma: a guide to the essentials of good clinical practice. Paris, France: International Union Against Tuberculosis and Lung Disease, 2005. Available at: http://www.iuatld.org
38. Ait-Khaled N, Auregan G, Bencharif N, Camara LM, Dagli E, Djankine K et al. Affordability of inhaled corticosteroids as a potential barrier to treatment of asthma in some developing countries. Int J Tuberc Lung Dis 2000;4:268-271.
39. Burney P. Global Asthma Survey on Practice. 35th Union World Conference on Lung Health; 28 Oct-1 Nov 2004, Paris, France (personal communication).
40. Schatz M, Cook EF, Joshua A, Petitti D. Risk factors for asthma hospitalizations in a managed care organization: development of a clinical prediction rule. Am J Manag Care 2003;9:538-547.
41. Ather S, Chung KD, Gregory P, Demissie K. The association between hospital readmission and insurance provider among adults with asthma. J Asthma 2004;41:709-713.
42. Billo N. Do we need an Asthma Drug Facility? Int J Tuberc Lung Dis 2004;8:391.
43. Billo NE. Asthma Drug Facility: from concept to reality. Int J Tuberc Lung Dis 2006;10:709.
44. Trébucq A, Rambert C. A guide for the procurement of anti-tuberculosis drugs. Paris, France: International Union Against Tuberculosis and Lung Disease, 2001. Available at: http://www.iuatld.org
45. Kumaresan J, Smith I, Arnold V, Evans P. The global TB drug facility: innovative global procurement. Int J Tuberc Lung Dis 2004;8:130-138.
46. Lavallée M. Transition vers des aérosols-doseurs sans CFC: comment s'y retrouver? Pharmactuel 2003;36:113-114.
47. Dolovich M. New delivery systems and propellants. Can Respir J 1999;6:290-295.
48. Clark DJ, Lipworth BJ. Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. Br J Clin Pharmacol 1996;41:247-249.
49. Baumgarten CR, Dorow P, Weber HH, Gebhardt R, Kettner J, Sykes AP, German Study Group. Equivalence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. Respir Med 2000;94 (Suppl B):S17-21.
50. Donnell D, Harrison LI, Ward S, Klinger NM, Ekholm BP, Cooper KM et al. Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler. Eur J Clin Pharmacol 1995;48:473-477.
51. Kleerup EC, Tashkin DP, Cline AC, Ekholm BP. Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma. Chest 1996;109:702-707.
52. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998;12:1346-1353.
53. Derom E, Pauwels RA. Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. Clin Pharmacokinet 2005;44:815-836.
54. Holz O, Zuhlke I, Einhaus M, Welker L, Kanniess F, Branscheid D et al. Direct measurement of BDP and 17-BMP in bronchial and peripheral lung tissue after inhalation of HFA- vs CFC-driven aerosols. Pulm Pharmacol Ther 2004;17:233-238.
55. Boulet LP, Cartier A, Ernst P, Larivee P, Laviolette M. Safety and efficacy of HFA-134a beclomethasone dipropionate extra-fine aerosol over six months. Can Respir J 2004;11:123-130.
56. Demedts M, Cohen R, Hawkinson R Switch to non-CFC inhaled corticosteroids: a comparative efficacy study of HFA-BDP and CFC-BDP metereddose inhalers. Int J Clin Pract 1999;53:331-338.
57. Fireman P, Prenner BM, Vincken W, Demedts M, Mol SJ, Cohen RM. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Ann Allergy Asthma Immunol 2001;86:557-565.
58. Harrison LI, Colice GL, Donnell D, Soria I, Dockhorn R. Adrenal effects and pharmacokinetics of CFC-free beclomethasone dipropionate: a 14-day dose-response study. J Pharm Pharmacol 1999;51:263-269.
59. Ederle K, Multicentre Study Group. Improved control of asthma symptoms with a reduced dose of HFA-BDP extrafine aerosol: an open-label, randomised study. Eur Rev Med Pharmacol Sci 2003;7:45-55.
60. Malone DC, Luskin AT. Hydrofluoroalkane-134a beclomethasone as a dominant economic asthma therapy. Respir Med 2003;97:1269-1276.
61. Price D, Haughney J, Duerden M, Nicholls C, Moseley C. The cost effectiveness of chlorofluorocarbon-free beclomethasone dipropionate in the treatment of chronic asthma: a cost model based on a 1-year pragmatic, randomised clinical study. Pharmacoeconomics 2002;20:653-664 (Erratum in: Pharmacoeconomics 2002;20:853).
62. World Health Organization. Preventing chronic diseases: a vital investment: WHO Global Report. Geneva: World Health Organization, 2005 (ISBN 92 4 156300 1).
63. Global Alliance against Chronic Respiratory Diseases (GARD). Available at: http://www.who.int/respiratory/gard/launch/en/index.html (Accessed 1 December 2006).